Figure legends lists
Figure 1. Patient recruitment flowchart
Figure 2. Kaplan‐Meier curve showing progression‐free survival for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy
Figure 3. Kaplan‐Meier curves showing progression‐free survival for Toripalimab‐, Camrelizumab and Sintilimab‐treated patients
Figure 4. Kaplan‐Meier curve showing time to progression for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy
Figure 5. Kaplan‐Meier curves showing time to progression for Toripalimab‐, Camrelizumab and Sintilimab‐treated patients
Figure 6. Kaplan‐Meier curve showing overall survival for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy
Figure 7. Kaplan‐Meier curves showing overall survival for Toripalimab‐, Camrelizumab and Sintilimab‐treated patients